CureVac
CureVac40About
What does CureVac do?
CureVac is a biopharmaceutical company focused on developing and commercializing novel mRNA-based vaccines and therapeutics. Their technology platform enables the development of treatments for a range of diseases, including infectious diseases and cancer, by leveraging the body's own cells to produce therapeutic proteins.
What is CureVac's revenue?
StartupHub estimates CureVac's annual revenue at $302.4M (range $120.6M to $895.0M, 28% confidence), based on comparable companies in the sector.
What is CureVac's valuation?
StartupHub estimates CureVac's effective valuation at $7.8B (range $5.2B to $12.4B, 10% confidence), based on comparable companies in the sector.
How much funding has CureVac raised?
CureVac has raised a total of $2.1B in funding. The most recent round on record is IPO.
Where is CureVac headquartered?
CureVac is headquartered in Tübingen, Germany.
When was CureVac founded?
CureVac was founded in 2000.
What industry does CureVac operate in?
CureVac operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Vaccines.
No comments yet. Be the first to share your take.